September 25, 2016 3:08 AM ET

Biotechnology

Company Overview of Chroma Therapeutics Ltd.

Company Overview

Chroma Therapeutics Ltd., a biotechnology company, focuses on the discovery and development of novel small molecule drugs based on chromatin biology and novel cell accumulation approaches for targeted cancer and inflammation treatments. Its products under pipeline include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor for the treatment of cancer; and CHR-2845, a targeted solution for haemotological malignancies. The company was founded in 2000 and is based in Abingdon, United Kingdom.

93 Innovation Drive

Milton Park

Abingdon,  OX14 4RZ

United Kingdom

Founded in 2000

Phone:

44 1235 829120

Fax:

44 1235 829125

Key Executives for Chroma Therapeutics Ltd.

Founder and Member of Scientific Advisory Board
Age: 58
Founder and Member of Scientific Advisory Board
Director of Pre-Clinical Development
Chief Scientific Officer
Compensation as of Fiscal Year 2016.

Chroma Therapeutics Ltd. Key Developments

CTI Acquires Exclusive Worldwide License to Tosedostat Through Concurrent Transactions with Vernalis R&D Limited and Chroma Therapeutics Ltd

CTI BioPharma Corp. announced that it has acquired worldwide rights to tosedostat through concurrent transactions with Vernalis R&D Limited and Chroma Therapeutics Ltd. Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. Tosedostat is currently being evaluated in multiple Phase 2 clinical trials for the treatment of patients with Acute Myeloid Leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS), which are intended to inform the design for a Phase 3 registration study to support potential regulatory approval. Over the next year, CTI and its advisors intend to develop a registration path for tosedostat in the US and Europe. Chroma and CTI also terminated their prior license agreement relating to tosedostat, thereby eliminating potential future developmental and sales milestone payments by CTI of up $209 million thereunder. Concurrently, CTI entered into a license agreement with Vernalis for the exclusive worldwide right to use certain patents and other intellectual property rights to develop, market and commercialize tosedostat and certain other analogues. Under the Vernalis license agreement, CTI agreed to make tiered royalty payments of no more than a high single-digit percentage, on a country-by-country basis, for the longer of ten years following commercial launch or the expiration of relevant patents.

Similar Private Companies By Industry

Company Name Region
Abcodia Ltd. Europe
Abeterno Ltd. Europe
Abgentis Ltd. Europe
ADC Biotechnology Ltd Europe
Advanced Gel Technology Limited Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Chroma Therapeutics Ltd., please visit www.chromatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.